Effect of rosuvastatin therapy on high-sensitivity C-reactive protein values and lipid profile in hyperlipidemic patients: A prospective study

Rovustatin therapy, hs-CRP and lipid profile

Abstract

Background/Aims: Although many studies show statins' C-reactive protein (CRP) lowering effect, results are often inconsistent. To clarify this issue, we investigated the effect of rosuvastatin treatment on serum hs-CRP levels and the possible relationships between lipid profile and hs-CRP levels in hyperlipidemic patients before and after treatment.

Methods: A total of 123 patients diagnosed with hyperlipidemia were analyzed in this prospective study. All patients were administered oral 20 mg/day rosuvastatin for 12 weeks. The hs-CRP levels and lipid profile changes at baseline and the end of 12 weeks of treatment were evaluated.

Results: Seventy-five female and 48 male patients were included in our study, and the mean age was 53.91 ± 8.08 years. We found that post-treatment total cholesterol, triglyceride, low-density lipoprotein cholesterol, hs-CRP levels and total cholesterol / high-density lipoprotein cholesterol ratio were significantly lower than baseline. In contrast, HDL-C levels were significantly higher (p=0.001 for all parameters).

Conclusion: Considering the established prognostic effects of dyslipidemia, the increasingly definite effects of hs-CRP in cardiovascular diseases, and our results, which were in agreement with previous studies, it is evident that statins reduce inflammation as improving cholesterol levels in patients with hyperlipidemia.